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Conclusion: The analysis proposed can be used to perform 
automatic detection of MLC errors ≥0.5mm based on 
individual Linac performance characteristics. Automatic 
detection of MLC errors has potential in reducing costs and 
downtime in external beam radiotherapy. 
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Purpose or Objective: To assess the feasibility of using 
radiochromic film to aid the calorimetric determination of 
the dose-area product (DAP) in small fields by determining 
the uncertainty in film DAP measurements. 
 
Material and Methods: Dose measurements in small fields 
can be problematic. DAP methods with a detector much 
larger than the radiation field provide an alternative to 
conventional central-axis (CAX) dose measurements. DAP is 
the integrated dose over the area of the detector (Equ. 1) 
with units of Gy.cm2. In order to convert the measured DAP 
to the CAX dose the equivalent area of the beam is required. 
This is the area of an equivalent field with no penumbra (i.e. 
a step function profile). 
 
(1) 
Out of field doses can contribute considerably to the total 
dose when the detector is integrating over an area much 
larger than the field size. Film exposures with centimetre-
sized fields were performed on the Imaging and Medical 
Beamline (IMBL) at the Australian Synchrotron using HD-V2 
radiochromic film. Films were scanned using an Epson V700 
flatbed scanner. The equivalent beam area was calculated by 
two methods: by normalising the 2D optical density data to 
unity and either (a) integrating over the area of the detector, 
or (b) integrating horizontal and vertical profiles and 
calculating an area by the product of width and height. 
Uncertainties have been assessed for scan repeatability, 
scanner corrections, scanning conditions of calibration films, 
selection of normalisation value and the dynamic range of 
the film. 
 
Results: The most important contribution to the uncertainty 
in DAP measurements is the calculation of the beam area. In 
the IMBL beam dose rates are typically 50 – 3000 Gy/s 
depending on distance from the source. High dose film such 
as HD-V2 is necessary to measure the large doses, however 
the dynamic range of the film is not suited to low dose 
measurements. 
Preliminary measurements suggest an uncertainty of 1% to 
1.5% in the background dose (relative to CAX dose) can be 
expected. For a 10x10 mm2 field measured with a detector 
40 mm in diameter, a 1% uncertainty in background dose will 
result in a 12% uncertainty in DAP measurement. This is likely 
to be the limiting factor for DAP film measurements.  
Scan repeatability, scanner light intensity variation in the 
horizontal plane, scanner resolution and air gap between film 
and scanner window all introduce small uncertainties. These 
can be reduced by using systematic scanning techniques and 
averaging over multiple scans. 
 
Conclusion: Determination of the out of field dose was found 
to the dominant uncertainty in film DAP measurements. 
Further work is required to determine if a two-film approach 
can improve the uncertainty. The desired accuracy of <5% 
will require additional steps to reduce the uncertainty in the 
out of field dose. 
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Purpose or Objective: Pre-treatment evaluation of RapidArc 
plans with three different methods: Portal Dosimetry, Delta4 
and Epiqa and comparative study. 
 
Material and Methods: RapidArc plans are calculated by 
Eclipse V.10 AAA algorithm and treatments are delivered by 
Varian Clinac iX and 2100 accelerators. The pretreatment 
verification methods are Portal Dosimetry by Varian, 3D 
detector Delta4 by ScandiDos and the software Epiqa by 
EPIdos.  
 
Results: The comparative study is carried out on 100 
patients. The acceptance criteria used for gamma analysis 
are: local, dose difference from 3% to 4% and distance-to-
agreement from 3mm to 4mm. 
For Head & Neck treatments, the average value of Gamma 
Agreement Index (GAI) given by Portal Dosimetry is 98,17% 
with standard deviation of 1,41%, Delta4 gives 97,77% with 
standard deviation of 1,52% and Epiqa 97,54% with standard 
deviation of 1,60%. 
For Pelvis treatments, the average value of Gamma 
Agreement Index (GAI) given by Portal Dosimetry is 98,09% 
with standard deviation of 1,54%, Delta4 gives 98,19% with 
standard deviation of 1,30% and Epiqa 97,83% with standard 
deviation of 1,84%. 
For Encephalon treatments, the average value of Gamma 
Agreement Index (GAI) given by Portal Dosimetry is 98,31% 
with standard deviation of 1,49%, Delta4 gives 98,04% with 
standard deviation of 1,56% and Epiqa 99,01% with standard 
deviation of 1,38%. 
For Thorax & Abdomen treatments, the average value of 
Gamma Agreement Index (GAI) given by Portal Dosimetry is 
97,57% with standard deviation of 1,77%, Delta4 gives 97,92% 
with standard deviation of 1,41% and Epiqa 97,96% with 
standard deviation of 1,58%. 
Then, intentional errors were introduced in 3 plans in order 
to evaluate the capacity of each method to detect these 
errors. It was errors in terms of Monitor Units (MU) and 
